Table 2.
Selected clinical features of vitiligo patients and serum Cu and Zn levels
| Group | Cu (μg/ dl) Median |
Cu (μg/dl) Mean ± SD |
Pa | Zn (μg/ dl) Median |
Zn (μg/dl) Mean ± SD |
Pa | [Cu]/[Zn] | pa |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Early Onset < 50 (59.83%) | 95.07 | 107.12 ± 61.17 | 0.035 | 72.56 | 83.06 ± 49.89 | 0.001 | 1.96 ± 1.44 | 0.164 |
| Late Onset >50 (40.17%) | 138.37 | 122.53 ±56.30 | 100.23 | 112.81± 67.19 | 1.72 ± 2.13 | |||
|
| ||||||||
| Early-Onset (<50 y) | ||||||||
| Male (23.9%) | 98.41 | 110.78± 62.80 | 0.189 | 76.92 | 89.70±45.13 | 0.008 | 1.73± 1.61 | 0.00 |
| Female (35.8%) | 90.04 | 116.54±54.15 | 68.96 | 78.63±52.90 | 1.77± 2.00 | |||
|
| ||||||||
| Late-Onset (>50 Y) | ||||||||
| Male (17.1%) | 131.69 | 119.65±57.57 | 0.017 | 88.58 | 113.54±78.26 | 0.629 | 1.49 ± 1.11 | 0.005 |
| Female (24.7%) | 128.67 | 124.52±56.34 | 100.23 | 112.27± 59.25 | 2.54±2.79 | |||
|
| ||||||||
| Clinical type | ||||||||
| Generalized (82.9%) | 101.96 | 111.63±54.18 | 0.04 | 73.01 | 93.11±59.33 | 0.006 | 1.88±2.02 | 0.078 |
| Localized (17.09%) | 104.72 | 120.74 ±71.64 | 110.50 | 98.69±58.63 | 1.40±1.24 | |||
|
| ||||||||
| Skin phototype | ||||||||
| Skin type I and II (0%) | ||||||||
| Skin type III (69.93%) | 103.41 | 112.67±59.66 | 0.113 | 84.68 | 99.24± 59.91 | 0.015 | 1.48± 1.16 | 0.00 |
| Skin type IV (29.97%) | 103.61 | 117.04± 59.95 | 67.32 | 86. 16±60.62 | 2.45±2.75 | |||
|
| ||||||||
| History of other auto immune disease | ||||||||
| Yes (6.84%) | 136.36 | 143.99±62.61 | 0.001 | 74.48 | 98.29±68.92 | 0.008 | 2.08±1.33 | 0.00 |
| No (93.16%) | 98.15 | 111.34±58.89 | 77.08 | 94.71± 58.59 | 1.79± 1.96 | |||
|
| ||||||||
| Smoking status | ||||||||
| Smokers (16.23%) | 99.86 | 106.93 ± 57.08 | 0.023 | 74.03 | 99.67 ± 59.49 | 0.05 | 1.71± 1.63 | 0.273 |
| Non-smokers (83.76%) | 103.51 | 115.45 ± 60.20 | 76.25 | 94.34± 59.50 | 1.83±1.95 | |||
Cu = copper; SD = standard deviation; Y = years; Zn = zinc.
Pa, case –case comparison.